Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

The takeaway for investors is that Viking Therapeutics has the potential to be a multi-bagger stock in time. As of April 15, ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Viking Therapeutics (NasdaqCM:VKTX) saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.

Fintel reports that on April 8, 2025, Goldman Sachs initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

VKTX is still down 39.3% in 2025, hitting a more than 12-month bottom of $18.92 on April 9. Today's breakout has the shares ...

Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Value Investor model based on the published ...